Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6 small nuclear 94, pseudogene (RNU6-94P) is classified as a **pseudogene** of the U6 small nuclear RNA (snRNA), specifically the 94th documented copy in the human genome[4][6]. U6 snRNA is a highly conserved, noncoding RNA that is a central component of the spliceosome—the macromolecular complex responsible for removing introns from pre-mRNA in eukaryotic cells[1][5]. However, as a **pseudogene**, RNU6-94P does not produce a functional RNA or protein product and lacks intrinsic biological or therapeutic activity[4]. Pseudogenes such as RNU6-94P are generally regarded as genomic relics generated by retrotransposition events—often involving LINE-1 retrotransposons—that integrate RNA-derived sequences back into the genome[3][7]. These copies are typically transcriptionally inactive, do not contribute to spliceosome function, and have no established roles in disease or therapy. They may, however, serve as genomic markers for studying retrotransposon dynamics and genome evolution[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 94, pseudogene (RNU6-94P).